Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 21, 2022, titled "Glenmark is the first company to launch in India a Triple FDC of Teneligliptin +Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance".